Kemik Sağlığı ve Renal Replasman Tedavileri: En İyisi Hangisi?

Öz

Amaç: Çalışmada, son dönem böbrek yetmezliği hastalarında renal replasman tedavilerinin kemik sağlığı açısından etkinlik ve güvenilirliklerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya 27 hemodiyaliz HD, Grup 1 , 51 periton diyalizi PD, Grup 2 , 25 böbrek nakli Rtx, Grup 3 hastası ve 40 sağlıklı kontrol grubu Grup 4 alındı. Hastalar ve kontrol grubunun intakt parathormon iPTH , fibroblast growth faktor 23 FGF-23 , osteoprotogerin OPG , osteokalsin OK , prokollagen tip-1 N terminal propeptid PINP , beta- crosslaps beta CTx , tartarat rezistan asid fosfataz TRAF5b , kemik alkalen fosfataz KAF , 1,25 OH D3 ve 25 OH D3 düzeyleri ölçüldü. α-Klotho gen mutasyonu F352V gerçek zaman PCR ve yüksek çözünürlüklü erime yöntemi kullanılarak değerlendirildi. Bulgular: α- klotho gen polimorfizmi wild/heterezigot/mutasyon: 22 %81,5 / 0 %0 / 5 %18,5 ve FGF23 düzeylerinin G1-2-3-4 sırayla; 1252±310/ 872±526/ 34,6 1,3-986 / 82 23-991 HD hastalarında diğer tüm gruplardan anlamlı derecede daha yüksek olduğu görüldü. 1,25 OH D3 ve 25 OH D3 düzeylerinin HD ve PD hastalarında diğer gruplardan daha düşük, G3-G4 arasında benzer olduğu görüldü. iPTH, FGF-23, OPG, OC ve TRAP5b düzeylerinin G1 ve G2 hastalarında diğer gruplardan daha yüksek, PINP ve beta CTx düzeylerinin G1’de en yüksek, kemik mineral yoğunluğu KMY ise G1’de en düşük iken G2-G3, G2-G4 ve G3-G4 arasında benzer olduğu görüldü. Sonuç: Çalışmamızda böbrek naklinin; son dönem böbrek yetmezliği hastaları için kemik sağlığı αklotho gen polimorfizmi, FGF23 düzeyleri, kemik metabolizma markırları ve kemik mineral yoğunluğu açısından en etkin ve güvenilir renal replasman tedavisi olduğu gösterilmiştir

Anahtar Kelimeler

• Periton diyalizi, Hemodiyaliz, Böbrek nakli, FGF-23, α- klotho gen polimorfizmi, Kemik mineral yoğunluğu

Bone Health and Renal Replacement Therapies: Which are the Best?

Abstract

Objective: The aim of this study was to evaluate the efficacy and safety of renal replacement therapy modalities in terms of bone health for end-stage renal disease patients.Material and Methods: We included 27 hemodialysis group 1 , 51 chronic peritoneal dialysis group 2 , and 25 renal transplant patients group 3 and 40 healthy subjects control, group 4 in the study. Intact parathormone iPTH , fibroblast growth factor 23 FGF-23 , osteoprotogerin OPG , osteocalcin OC , procollagen type-1 N terminal propeptide PINP , beta- crosslaps beta CTx , tartarate resistant acid phosphatase TRAP5b , bone alkaline phosphatase BAP , 1,25 OH D3 and 25 OH D3 levels were measured in the patients and the control group. The α-Klotho gen mutation F352V was evaluated by real-time PCR and the high-resolution melting method.results: The α-Klotho gene polymorphism rates wild/heterozygote/mutation: 22 81.5% / 0 0% / 5 18.5% and FGF23 levels G1-2-3-4 1252±310 / 872±526 / 34.6 / 82 respectively were significantly higher in group 1. The 1.25 OH D3 and 25 OH D3 levels were lower in groups 1 and 2 but similar in group 3 and 4. The iPTH, FGF-23, OPG, OC and TRAP5b levels were significantly higher in Group 1 and 2. The PINP and beta CTx levels were highest in group 1. BMD level was lowest in group 1 and similar in groups 2-3, groups 2 and 4 and groups 3-4. conclusion: This study showed that renal transplantation is the most effective and safe renal replacement therapy modality in terms of bone health α-Klotho gene polymorphism, FGF-23 levels, indicators of bone metabolism and bone mineral density for end-stage renal disease patients

Keywords

• Peritoneal dialysis, Hemodialysis, Renal transplantation, FGF-23, α-Klotho gene polymorphism, Bone mineral density

Kaynakça

1. 1. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-92.
2. 2. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease.Kidney Int Suppl 2009;114:S34- 42.
3. 3. Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology (Carlton) 2011;16:261-8.
4. 4. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast Growth Factor-23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-52.
5. 5. Jongbloed F, Galassi A, Cozzolino M, Zietse R, Chiarelli G, Cusi D, Brancaccio D, Gallieni M. Clinical significance of FGF-23 measurement in dialysis patients. Clin Nephrol 2011;76:201-9.
6. 6. Huang CL. Regulation of ion channels by secreted Klotho: Mechanisms and implications. Kidney Int 2010;77:855-60.
7. 7. Cozzolino M, Galassi A, Apetrii M, Covic A. What would we like to know, and what do we not know about fibroblast growth factor 23. J Nephrol 2011;24:696-706.
8. 8. Choi BH, Kim CG, Lim Y, Lee YH, Shin SY. Transcriptional activation of the human Klotho gene by epidermal growth factor in HEK293 cells; role of Egr-1. Gene 2010;450:121- 7.

9. 9. Adijiang A, Niwa T. An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 2010;31:160-4.
10. 10. Torres PU, Prié D, Molina-Blétry V, Beck L, Silve C, Friedlander G. Klotho: An antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007;71:730- 7.
11. 11. Bostrom MA, Hicks PJ, Lu L, Langefeld CD, Freedman BI, Bowden DW. Association of polymorphisms in the klotho gene with severity of non-diabetic ESRD in African Americans. Nephrol Dial Transplant 2010;25:3348-55.
12. 12. Oguro R, Kamide K, Kokubo Y, Shimaoka I, Congrains A, Horio T, Hanada H, Ohishi M, Katsuya T, Okamura T, Miyata T, Kawano Y, Rakugi H. Association of carotid atherosclerosis with genetic polymorphisms of the klotho gene in patients with hypertension. Geriatr Gerontol Int 2010;10:311-8.
13. 13. Shimoyama Y, Taki K, Mitsuda Y, Tsuruta Y, Hamajima N, Niwa T. KLOTHO gene polymorphisms G-395A and C1818T are associated with low-density lipoprotein cholesterol and uric acid in Japanese hemodialysis patients. Am J Nephrol 2009;30:383-8.
14. 14. Kim Y, Jeong SJ, Lee HS, Kim EJ, Song YR, Kim SG, Oh JE, Lee YK, Seo JW, Yoon JW, Koo JR, Kim HJ, Noh JW, Park SH. Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients. Korean J Intern Med 2008;23:201-7.
15. 15. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. Peripheral vascular calcification in long-haemodialysis patients: Associated factors and survival consequences. Nephrol Dial Transplant 2009;24:948-55.
16. 16. Viaene L, Bammens B, Meijers BK, Vanrenterghem Y, Vanderschueren D, Evenepoel P. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 2012;27:2017-22.
17. 17. Bacchetta J, Dubourg L, Harambat J, Ranchin B, AbouJaoude P, Arnaud S, Carlier MC, Richard M, Cochat P. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010;95:1741-8.
18. 18. Trombetti A, Richert L, Hadaya K, Graf JD, Herrmann FR, Ferrari SL, Martin PY, Rizzoli R. Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011;164:839-47.
19. 19. Milinković NLj, Majkić-Singh NT, Mirković DD, Beletić AD, Pejanović SD, Vujanić ST. Relation between 25(OH)- vitamin D deficiency and markers of bone formation and resorption in haemodialysis patients. Clin Lab 2009;55:333- 9.
20. 20. Kurnatowska I, Grzelak P, Kaczmarska M, Stefańczyk L, Nowicki M. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011;117:297- 304.
21. 21. Mesquita M, Demulder A, Wolff F, Mélot C, Damry N, Dratwa M, Bergmann P. Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc 2010;42:3444-9.
22. 22. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002;40:802-9.
23. 23. Inaba M, Okuno S, Nagasue K, Otoshi T, Kurioka Y, Maekawa K, Kumeda Y, Imanishi Y, Ishimura E, Ohta T, Morii H, Kim M, Nishizawa Y. Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am J Kidney Dis 2001;38:139-42.
24. 24. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V; NECOSAD Study Group. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011;6:1752-9.
25. 25. Kitazawa S, Kajimoto K, Kondo T, Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 2003;89:771-7.
26. 26. Johnson DW, McIntyre HD, Brown A, Freeman J, Rigby RJ. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996;16:34-40.
27. 27. Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W, Sowinski J. Bone mass in chronic renal insufficiency patients treated with continuous ambulatory peritoneal dialysis. Adv Perit Dial 2001;17:109-13.
28. 28. Pasadakis P, Thodis E, Manavis J, Mourvati E, Panagoutsos S, Vargemezis V. The identification of bone mineral density in CAPD in comparison with HD patients. Adv Perit Dial 1995;12:247-53.
29. 29. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G. A comparison of quantitative computed tomography and dual x-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001;37:1247-52.
30. 30. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218-26.
31. 31. Taal MW, Masud T, Gren D, Cassidy MJ. Risk factors for reduced bone density in hemodialysis patients. Nephrol Dial Transplant 1999;14:1922-8.
32. 32. Ureña P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, de Vernejoul MC. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003;18:2325-31.
33. 33. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-93.
34. 34. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis PK, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman R, Vlachojannis JG, Dombros AN, Utaş C, Akpolat T, Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis PC, Yavuz M, Tsakiris JD, Dimitriades CA, Yilmaz ME, Gültekin M, Karayalçin B, Yardimsever M, Oreopoulos DG. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006;24:79-86.
35. 35. Peter R. Ebeling. Approach to the patient with transplantation-related bone loss. Journal of Clinical Endocrinology & Metabolism 2009;94:1483-90.
36. 36. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol 2004;24:82-90.
37. 37. Yu RW, Faull RJ, Coates PT, Coates PS. Calcium supplements lower bone resorption after renal transplant. Clin Transplant 2012;26:292-9.
38. 38. Sánchez González MC, Fernandez Giraldez E, Valdivielso Revilla JM. Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis. Nefrologia 2008;28:39-45.
39. 39. Stompór T. An overview of the pathophysiology of vascular calcification in chronic kidney disease. Perit Dial Int 2007;27:215-22.
40. 40. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 2010;78:1024- 32. Epub 2010 Aug 4.
41. 41. Komaba H, Koizumi M, Fukagawa M. Parathyroid resistance to FGF23 in kidney transplant recipients: Back to the past or ahead to the future? Kidney Int 2010;78:953-5.
42. 42. Economidou D1, Dovas S, Papagianni A, Pateinakis P, Memmos D. FGF-23 Levels before and after Renal Transplantation. J Transplant 2009;2009:379082.
43. 43. Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant 2011;26:3779-84.
44. 44. Kanaan N, Claes K, Devogelaer JP, Vanderschueren D, Depresseux G, Goffin E, Evenepoel P. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010;5:1887-92.
45. 45. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
46. 46. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
47. 47. Hjelmesaeth J, Ueland T, Flyvbjerg A, Bollerslev J, Leivestad T, Jenssen T, Hansen TK, Thiel S, Sagedal S, Røislien J, Hartmann A. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006;17:1746-54.
48. 48. Bargnoux AS, Dupuy AM, Garrigue V, Jaussent I, Gahide G, Badiou S, Szwarc I, Deleuze S, Vernhet H, Cristol JP, Mourad G. Evolution of coronary artery calcifications following kidney transplantation: Relationship with osteoprotegerin levels. Am J Transplant 2009;9:2571-9.
49. 49. Malyszko J, Malyszko JS, Wolczynski S, Mysliwiec M. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc 2003;35:2227-9.
50. 50. Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G. Renal transplantation decreases osteoprotegerin levels. Transplant Proc 2006;38:2317-8.
51. 51. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H, Moriguchi A, Nishizawa Y. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem 2001;47:1410-4.
52. 52. Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008;82:278-87.
53. 53. Marcén R, Ponte B, Rodríguez-Mendiola N, FernándezRodriguez A, Galeano C, Villafruela JJ, Teruel JL, Burgos FJ, Ortuño J. Vitamin D deficiency in kidney transplant recipients: risk factors and effects of vitamin D3 supplements. Transplant Proc 2009;41:2388-90.
54. 54. Stein EM, Shane E. Vitamin D in organ transplantation. Osteoporos Int 2011;22:2107-18.
55. 55. Cunningham J. Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. J Am Soc Nephrol 2007;18:223-34.
56. 56. Lim DS, Kee TY, Fook-Chong S, Zhang RF, Chandran M. Prevalence and patterns of bone loss in the first year after renal transplant in South East Asian patients. Transplantation 2011;92:557-63.